Skip to content
Home/Companies/Biotech/GQ Bio Therapeutics

GQ Bio Therapeutics

Biotech·Germany·Exited 2025·Held 13yr
Entry
2012
Hold
13yr
Exit
2025

Who owns GQ Bio Therapeutics?

GQ Bio Therapeutics was owned by IFB Innovationsstarter through Innovationsstarter Fonds Hamburg I (2012 vintage) from 2012 to 2025, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-03

IFB Innovationsstarter
Investor
IFB Innovationsstarter
Innovationsstarter Fonds Hamburg I · 2012 · VC

Key facts

HQGermany
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2025

More from Innovationsstarter Fonds Hamburg I

Other portfolio companies in the same fund.

bentekk
Exited 2017
IndustrialsGermany· 2016
to
Protembis
Protembis
Active
MedTechGermany· 2015
i3 Membrane
i3 Membrane
Active
MedTechGermany· 2014
CustomCells
CustomCells
Exited 2025
ClimateTechGermany· 2013
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track GQ Bio Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy GQ Bio Therapeutics?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on GQ Bio Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue